Carpal Tunnel Syndrome (CTS)NCT06952647
Hematological and Metabolic Markers in Carpal Tunnel Syndrome
An observational study of Carpal Tunnel Syndrome (CTS) and Biomarkers / Blood, run by Ankara Training and Research Hospital at 1 site in Turkey (Türkiye).
Trial summary
Carpal tunnel syndrome (CTS) is the most common entrapment neuropathy, but the severity of symptoms experienced by patients does not always correspond to abnormalities detected by nerve conduction studies. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Carpal Tunnel Syndrome (CTS), Biomarkers / Blood
- How many people
- 197 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 20 Apr 2025to 1 Jun 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Patients referred to the Electromyography (EMG) laboratory/clinic with suspected Carpal Tunnel Syndrome (CTS) who underwent electrodiagnostic testing
Who may be able to join
- Age between 18-65 years
- Having undergone Electromyography (EMG) testing for Carpal Tunnel Syndrome (CTS)-like symptoms
- Recent complete blood count, C-Reactive Protein (CRP), and albumin available
Who cannot join
- Age below 18 or above 65 years
- Pregnancy
- History of wrist trauma or surgical operation
- Chronic kidney disease
- Gout
- Rheumatoid arthritis
Show all 15Show fewer
- Connective tissue disease
- Thyroid disorders
- Acromegaly
- Polyneuropathy
- Thoracic outlet syndrome
- Brachial plexopathy
- Cervical disc herniation
- Presence of cardiac pacemaker
- Steroid use
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Department of Physical Therapy and Rehabilitation, University of Health Sciences, Ankara Training and Research Hospital
Ankara, Altindag, 06230
About this study
Carpal tunnel syndrome (CTS) is the most common entrapment neuropathy, but the severity of symptoms experienced by patients does not always correspond to abnormalities detected by nerve conduction studies. This prospective cross-sectional study investigates whether routinely available metabolic, hematological, and inflammatory markers are associated with CTS and with patient-reported symptom and functional burden.
Adults referred for evaluation of suspected CTS were enrolled. Participants with electrodiagnostically confirmed CTS were compared with symptomatic individuals whose nerve conduction studies were normal. Clinical findings, Boston Carpal Tunnel Questionnaire scores, electrophysiological severity, and blood-based metabolic and inflammatory measures were evaluated. The study aims to better understand whether systemic metabolic and inflammatory factors contribute to the clinical expression of CTS beyond the degree of large-fiber nerve conduction abnormality.
Read the detailed description
Carpal tunnel syndrome (CTS) is the most common entrapment neuropathy and results from compression of the median nerve at the wrist. Although local mechanical compression is central to the disorder, the clinical presentation of CTS varies considerably. Patients with similar nerve conduction abnormalities may report very different levels of pain, paresthesia, weakness, and functional limitation. This variability suggests that systemic metabolic and inflammatory factors may contribute to the clinical expression of CTS in addition to the degree of median nerve conduction abnormality.
Several systemic conditions, including obesity, diabetes mellitus, thyroid disease, and inflammatory disorders, are associated with CTS. Obesity and metabolic dysfunction may increase peripheral nerve vulnerability through metabolic, vascular, and inflammatory mechanisms. Low-grade systemic inflammation has also been investigated as a possible contributor to CTS. Routinely available blood measurements may therefore provide additional information about systemic factors accompanying the disorder.
In recent years, several hematological indices derived from routine blood counts have been used as markers of systemic inflammatory activity. These include the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI). Metabolic and inflammation-related measures such as triglycerides, the triglyceride-to-high-density lipoprotein cholesterol ratio (TG/HDL), the C-reactive protein-to-albumin ratio (CAR), and the C-reactive protein-albumin-lymphocyte (CALLY) index may also reflect different aspects of systemic metabolic and inflammatory burden.
This prospective cross-sectional study includes adults referred for electrodiagnostic evaluation because of symptoms suggestive of CTS. Participants with electrodiagnostically confirmed median neuropathy at the wrist constitute the CTS group, while symptomatic individuals with normal nerve conduction studies serve as the comparison group. This design allows systemic markers associated with confirmed median nerve involvement to be examined against a clinically relevant symptomatic reference group rather than against asymptomatic healthy volunteers.
Clinical examination and nerve conduction studies are performed according to the study protocol. In participants with confirmed CTS, symptom severity and functional status are assessed using the Boston Carpal Tunnel Questionnaire (BCTQ). Routine hematological, biochemical, metabolic, and inflammatory measurements are obtained from fasting blood samples, and derived inflammatory and metabolic indices are calculated from their component variables.
The study evaluates three related but distinct clinical domains: the presence of electrodiagnostically confirmed CTS, patient-reported symptom and functional burden, and electrodiagnostic severity. The main objective is to determine whether routinely available metabolic and inflammatory measures are associated differently with these domains. In particular, the study examines whether systemic metabolic or inflammatory factors may help explain differences in patient-reported burden that are not fully captured by conventional nerve conduction findings.
- Conditions
- Carpal Tunnel Syndrome (CTS), Biomarkers / Blood
- Keywords
- Carpal Tunnel Syndrome (CTS), Biomarkers / blood, CALLY index, TG/HDL, Triglycerides
- Medical subject headings
- Carpal Tunnel Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Electrodiagnostically Confirmed CTS Group | Adults with symptoms suggestive of carpal tunnel syndrome and electrodiagnostic evidence of median neuropathy at the wrist. Participants were evaluated for clinical findings, patient-reported symptom and functional burden, electrodiagnostic severity, and fasting metabolic, hematological, and inflammatory measures. | |
| Symptomatic Electrodiagnostically Normal Control Group | Adults referred with symptoms suggestive of carpal tunnel syndrome but with normal nerve conduction studies. Participants were evaluated using the same clinical and fasting metabolic, hematological, and inflammatory measures as the CTS group and served as the symptomatic comparison group. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Evaluation of Systemic Inflammation Response Index (SIRI) as an Inflammatory Marker
The systemic inflammation response index (SIRI) is calculated as neutrophil count × monocyte count / lymphocyte count. It reflects the combined effect of neutrophil and monocyte-driven innate immunity versus lymphocyte-mediated adaptive immunity. SIRI has been proposed as a robust marker of inflammation in several chronic diseases.
In the current study, SIRI was evaluated in individuals with and without Carpal Tunnel Syndrome (CTS) to investigate its potential as an indicator of inflammatory burden.
Measured: up to 4 weeks
Secondary outcomes (7)
Comparison of TG/HDL
Comparison of TG/HDL between case and control groups
Measured: up to 4 weeks
Evaluation of Electrodiagnostic Severity of Carpal Tunnel Syndrome
Electromyography (EMG) is part of electrodiagnostic assessment used to evaluate peripheral nerve and muscle function. In this study, carpal tunnel syndrome severity was classified based on nerve conduction study findings as follows:
- Mild: Median-ulnar sensory distal latency difference >1.0 ms or median-ulnar fourth-digit peak sensory latency difference >0.5 ms.
- Moderate: Median motor distal latency >4.0 ms.
- Severe: Markedly reduced or absent median sensory nerve action potential, median motor amplitude <5.0 mV, or median motor distal latency >5.5 ms.
Measured: up to 4 weeks
- Comparison of C-Reactive Protein levels (CRP) and CALLY
- Comparison of C-Reactive Protein levels (CRP) levels between case and control groups. CRP is an acute phase protein used as an inflammatory marker. CRP's half-life is approximately 19 hours, making it a responsive marker that can indicate both the onset of inflammation and the response to treatment relatively quickly. CALLY (C-reactive protein-Albumin-Lymphocyte) index is a composite scoring system that integrates CRP, albumin, and lymphocyte count to reflect both inflammatory status and nutritional-immune condition simultaneously.
Measured: up to 4 weeks
Evaluation of Platelet/Lymphocyte Ratio (PLR) as an Inflammatory Marker
Platelet/lymphocyte ratio (PLR) is another hematological marker that reflects systemic inflammation. During inflammatory responses, platelet counts often increase while lymphocyte counts decrease, resulting in an elevated PLR. Platelets play an active role in inflammation by releasing inflammatory mediators and interacting with leukocytes. PLR, calculated from routine blood tests, has been increasingly used in the assessment of inflammatory conditions.
In this study, PLR values were compared between patients with Carpal Tunnel Syndrome (CTS) and healthy controls to evaluate its association with inflammation in CTS.
Measured: up to 4 weeks
Evaluation of Monocyte/Lymphocyte Ratio (MLR) as an Inflammatory Marker
Monocyte/lymphocyte ratio (MLR) is a peripheral blood marker used to assess systemic inflammatory status. Monocytes contribute to chronic inflammation and tissue remodeling, while lymphocytes are typically reduced in inflammatory states. An increased MLR may reflect an enhanced inflammatory response. Like other ratios, MLR can be easily derived from complete blood count parameters.
In this study, MLR was analyzed in patients with and without Carpal Tunnel Syndrome (CTS) to explore its relevance as a potential inflammatory biomarker.
Measured: up to 4 weeks
Evaluation of Neutrophil/Lymphocyte Ratio (NLR) as an Inflammatory Marker
In inflammatory diseases, the immune response often leads to an increase in circulating neutrophils and a decrease in lymphocytes, resulting in an elevated neutrophil/lymphocyte ratio (NLR). This parameter has recently gained attention as a simple, cost-effective, and readily available marker of systemic inflammation. NLR is derived from routine complete blood count tests and reflects the balance between innate (neutrophils) and adaptive (lymphocytes) immune responses.
In the present study, NLR was compared between patients with Carpal Tunnel Syndrome (CTS) and healthy controls to investigate its potential role as a marker of inflammation in CTS.
Measured: up to 4 weeks
Evaluation of Systemic Immune-inflammation Index (SII) as an Inflammatory Marker
The systemic immune-inflammation index (SII) is a composite marker calculated using the formula: platelet count × neutrophil count / lymphocyte count. It simultaneously incorporates three types of immune cells and is considered a more comprehensive indicator of the systemic inflammatory status. Elevated SII levels have been associated with various inflammatory and immune-mediated conditions.
In this study, SII values were compared between CTS patients and healthy controls to assess its potential utility in identifying inflammatory activity in CTS.
Measured: up to 4 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 May 2025
- Study start20 Apr 2025
- Primary completion1 Apr 2026
- Study completion1 Jun 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (14)Papers the sponsor has linked to this study.
- Other trials for Carpal Tunnel Syndrome (CTS)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 197 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ankara Training and Research Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Nadide Koca, Ankara Training and Research Hospital
- Investigators
- Nadide Koca, M.D., Principal investigator, University of Health Sciences, Ankara Training and Research Hospital, TURKEY
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06952647
- Sponsor's protocol ID
- AnkaraTRH-FTR-NK-04
- Status last verified
- Aug 2026
- First submitted
- 19 Apr 2025
- Last updated
- 25 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared due to institutional policies regarding patient privacy and data protection regulations
Publications
Che X, Chen Q, He D, Fan L. Correlation of CRP/Albumin ratio and low serum albumin with the risk of major adverse cardiovascular events in elderly patients with chronic total occlusion. Hereditas. 2025 Dec 29;163(1):19. doi: 10.1186/s41065-025-00622-1.
PubMed 41462402Razavi AS, Karimi N, Bashiri F. The relationship of serum lipid profiles and obesity with the severity of carpal tunnel syndrome. Pan Afr Med J. 2021 Jun 1;39:90. doi: 10.11604/pamj.2021.39.90.27234. eCollection 2021.
PubMed 34466192Yano K, Kawabata A, Ikeda M, Suzuki K, Kaneshiro Y, Egi T. Hypercholesterolemia Is Associated with the Subjective Evaluation of Postoperative Outcomes in Patients with Idiopathic Carpal Tunnel Syndrome Who Undergo Surgery: A Multivariate Analysis. Plast Reconstr Surg. 2018 Apr;141(4):941-948. doi: 10.1097/PRS.0000000000004228.
PubMed 29465486Zhu D, Lin YD, Yao YZ, Qi XJ, Qian K, Lin LZ. Negative association of C-reactive protein-albumin-lymphocyte index (CALLY index) with all-cause and cause-specific mortality in patients with cancer: results from NHANES 1999-2018. BMC Cancer. 2024 Dec 5;24(1):1499. doi: 10.1186/s12885-024-13261-y.
PubMed 39639229Tonga F, Bahadir S. The Factors Associated with Carpal Tunnel Syndrome Severity. Turk Neurosurg. 2022;32(3):392-397. doi: 10.5137/1019-5149.JTN.34519-21.2.
PubMed 34859834Zvonickova K, Rhee A, Sandy-Hindmarch O, Furniss D, Wiberg A, Schmid AB. Systemic low-grade C-reactive protein is associated with proximal symptom spread in carpal tunnel syndrome. Pain Rep. 2024 Apr 10;9(3):e1156. doi: 10.1097/PR9.0000000000001156. eCollection 2024 Jun.
PubMed 38606315Gunes M, Buyukgol H. Correlation of neutrophil/lymphocyte and platelet/lymphocyte ratios with the severity of idiopathic carpal tunnel syndrome. Muscle Nerve. 2020 Mar;61(3):369-374. doi: 10.1002/mus.26791. Epub 2020 Jan 9.
PubMed 31875987Wang RH, Wen WX, Jiang ZP, Du ZP, Ma ZH, Lu AL, Li HP, Yuan F, Wu SB, Guo JW, Cai YF, Huang Y, Wang LX, Lu HJ. The clinical value of neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), platelet-to-lymphocyte ratio (PLR) and systemic inflammation response index (SIRI) for predicting the occurrence and severity of pneumonia in patients with intracerebral hemorrhage. Front Immunol. 2023 Feb 13;14:1115031. doi: 10.3389/fimmu.2023.1115031. eCollection 2023.
PubMed 36860868Malakootian M, Soveizi M, Gholipour A, Oveisee M. Pathophysiology, Diagnosis, Treatment, and Genetics of Carpal Tunnel Syndrome: A Review. Cell Mol Neurobiol. 2023 Jul;43(5):1817-1831. doi: 10.1007/s10571-022-01297-2. Epub 2022 Oct 10.
PubMed 36217059Padua L, Cuccagna C, Giovannini S, Coraci D, Pelosi L, Loreti C, Bernabei R, Hobson-Webb LD. Carpal tunnel syndrome: updated evidence and new questions. Lancet Neurol. 2023 Mar;22(3):255-267. doi: 10.1016/S1474-4422(22)00432-X. Epub 2022 Dec 13.
PubMed 36525982Werner RA, Andary M. Carpal tunnel syndrome: pathophysiology and clinical neurophysiology. Clin Neurophysiol. 2002 Sep;113(9):1373-81. doi: 10.1016/s1388-2457(02)00169-4.
PubMed 12169318Otelea MR, Nartea R, Popescu FG, Covaleov A, Mitoiu BI, Nica AS. The Pathological Links between Adiposity and the Carpal Tunnel Syndrome. Curr Issues Mol Biol. 2022 Jun 8;44(6):2646-2663. doi: 10.3390/cimb44060181.
PubMed 35735622Joshi A, Patel K, Mohamed A, Oak S, Zhang MH, Hsiung H, Zhang A, Patel UK. Carpal Tunnel Syndrome: Pathophysiology and Comprehensive Guidelines for Clinical Evaluation and Treatment. Cureus. 2022 Jul 20;14(7):e27053. doi: 10.7759/cureus.27053. eCollection 2022 Jul.
PubMed 36000134Newington L, Harris EC, Walker-Bone K. Carpal tunnel syndrome and work. Best Pract Res Clin Rheumatol. 2015 Jun;29(3):440-53. doi: 10.1016/j.berh.2015.04.026. Epub 2015 May 27.
PubMed 26612240
Study at a glance
From the registry record, last updated by the sponsor on 25 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Hematological and Metabolic Markers in Carpal Tunnel Syndrome
- ClinicalTrials.gov ID
- NCT06952647
- Acronym / sponsor ID
- AnkaraTRH-FTR-NK-04
- Conditions
- Carpal Tunnel Syndrome (CTS), Biomarkers / Blood
- Keywords
- Carpal Tunnel Syndrome (CTS), Biomarkers / blood, CALLY index, TG/HDL, Triglycerides
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 197 participants (actual)
- Lead sponsor
- Ankara Training and Research HospitalUniversity, hospital or other
- Study start
- 20 Apr 2025 (actual)
- Primary completion
- 1 Apr 2026 (actual)
- Study completion
- 1 Jun 2026 (actual)
- First posted
- 1 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Carpal tunnel syndrome (CTS) is the most common entrapment neuropathy, but the severity of symptoms experienced by patients does not always correspond to abnormalities detected by nerve conduction studies. This prospective cross-sectional study investigates whether routinely available metabolic, hematological, and inflammatory markers are associated with CTS and with patient-reported symptom and functional burden.
Adults referred for evaluation of suspected CTS were enrolled. Participants with electrodiagnostically confirmed CTS were compared with symptomatic individuals whose nerve conduction studies were normal. Clinical findings, Boston Carpal Tunnel Questionnaire scores, electrophysiological severity, and blood-based metabolic and inflammatory measures were evaluated. The study aims to better understand whether systemic metabolic and inflammatory factors contribute to the clinical expression of CTS beyond the degree of large-fiber nerve conduction abnormality.
Detailed description
Carpal tunnel syndrome (CTS) is the most common entrapment neuropathy and results from compression of the median nerve at the wrist. Although local mechanical compression is central to the disorder, the clinical presentation of CTS varies considerably. Patients with similar nerve conduction abnormalities may report very different levels of pain, paresthesia, weakness, and functional limitation. This variability suggests that systemic metabolic and inflammatory factors may contribute to the clinical expression of CTS in addition to the degree of median nerve conduction abnormality.
Several systemic conditions, including obesity, diabetes mellitus, thyroid disease, and inflammatory disorders, are associated with CTS. Obesity and metabolic dysfunction may increase peripheral nerve vulnerability through metabolic, vascular, and inflammatory mechanisms. Low-grade systemic inflammation has also been investigated as a possible contributor to CTS. Routinely available blood measurements may therefore provide additional information about systemic factors accompanying the disorder.
In recent years, several hematological indices derived from routine blood counts have been used as markers of systemic inflammatory activity. These include the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI). Metabolic and inflammation-related measures such as triglycerides, the triglyceride-to-high-density lipoprotein cholesterol ratio (TG/HDL), the C-reactive protein-to-albumin ratio (CAR), and the C-reactive protein-albumin-lymphocyte (CALLY) index may also reflect different aspects of systemic metabolic and inflammatory burden.
This prospective cross-sectional study includes adults referred for electrodiagnostic evaluation because of symptoms suggestive of CTS. Participants with electrodiagnostically confirmed median neuropathy at the wrist constitute the CTS group, while symptomatic individuals with normal nerve conduction studies serve as the comparison group. This design allows systemic markers associated with confirmed median nerve involvement to be examined against a clinically relevant symptomatic reference group rather than against asymptomatic healthy volunteers.
Clinical examination and nerve conduction studies are performed according to the study protocol. In participants with confirmed CTS, symptom severity and functional status are assessed using the Boston Carpal Tunnel Questionnaire (BCTQ). Routine hematological, biochemical, metabolic, and inflammatory measurements are obtained from fasting blood samples, and derived inflammatory and metabolic indices are calculated from their component variables.
The study evaluates three related but distinct clinical domains: the presence of electrodiagnostically confirmed CTS, patient-reported symptom and functional burden, and electrodiagnostic severity. The main objective is to determine whether routinely available metabolic and inflammatory measures are associated differently with these domains. In particular, the study examines whether systemic metabolic or inflammatory factors may help explain differences in patient-reported burden that are not fully captured by conventional nerve conduction findings.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Electrodiagnostically Confirmed CTS Group | – | –Adults with symptoms suggestive of carpal tunnel syndrome and electrodiagnostic evidence of median neuropathy at the wrist. Participants were evaluated for clinical findings, patient-reported symptom and functional burden, electrodiagnostic severity, and fasting metabolic, hematological, and inflammatory measures. |
| Symptomatic Electrodiagnostically Normal Control Group | – | –Adults referred with symptoms suggestive of carpal tunnel syndrome but with normal nerve conduction studies. Participants were evaluated using the same clinical and fasting metabolic, hematological, and inflammatory measures as the CTS group and served as the symptomatic comparison group. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Patients referred to the Electromyography (EMG) laboratory/clinic with suspected Carpal Tunnel Syndrome (CTS) who underwent electrodiagnostic testing
Key inclusion criteria (3 listed)
- Age between 18-65 years
- Having undergone Electromyography (EMG) testing for Carpal Tunnel Syndrome (CTS)-like symptoms
- Recent complete blood count, C-Reactive Protein (CRP), and albumin available
Key exclusion criteria (15 listed)
- Age below 18 or above 65 years
- Pregnancy
- History of wrist trauma or surgical operation
- Chronic kidney disease
- Gout
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Evaluation of Systemic Inflammation Response Index (SIRI) as an Inflammatory Marker
Time frame: up to 4 weeks
The systemic inflammation response index (SIRI) is calculated as neutrophil count × monocyte count / lymphocyte count. It reflects the combined effect of neutrophil and monocyte-driven innate immunity versus lymphocyte-mediated adaptive immunity. SIRI has been proposed as a robust marker of inflammation in several chronic diseases. In the current study, SIRI was evaluated in individuals with and without Carpal Tunnel Syndrome (CTS) to investigate its potential as an indicator of inflammatory burden.
7 secondary outcomes
Comparison of TG/HDL
Time frame: up to 4 weeks
Evaluation of Electrodiagnostic Severity of Carpal Tunnel Syndrome
Time frame: up to 4 weeks
- Comparison of C-Reactive Protein levels (CRP) and CALLY
Time frame: up to 4 weeks
Evaluation of Platelet/Lymphocyte Ratio (PLR) as an Inflammatory Marker
Time frame: up to 4 weeks
Evaluation of Monocyte/Lymphocyte Ratio (MLR) as an Inflammatory Marker
Time frame: up to 4 weeks
Evaluation of Neutrophil/Lymphocyte Ratio (NLR) as an Inflammatory Marker
Time frame: up to 4 weeks
Evaluation of Systemic Immune-inflammation Index (SII) as an Inflammatory Marker
Time frame: up to 4 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Aug 2026.
- Background: PubMed 41462402Che X, Chen Q, He D, Fan L. Correlation of CRP/Albumin ratio and low serum albumin with the risk of major adverse cardiovascular events in elderly patients with chronic total occlusion. Hereditas. 2025 Dec 29;163(1):19. doi: 10.1186/s41065-025-00622-1.
- Background: PubMed 34466192Razavi AS, Karimi N, Bashiri F. The relationship of serum lipid profiles and obesity with the severity of carpal tunnel syndrome. Pan Afr Med J. 2021 Jun 1;39:90. doi: 10.11604/pamj.2021.39.90.27234. eCollection 2021.
- Background: PubMed 29465486Yano K, Kawabata A, Ikeda M, Suzuki K, Kaneshiro Y, Egi T. Hypercholesterolemia Is Associated with the Subjective Evaluation of Postoperative Outcomes in Patients with Idiopathic Carpal Tunnel Syndrome Who Undergo Surgery: A Multivariate Analysis. Plast Reconstr Surg. 2018 Apr;141(4):941-948. doi: 10.1097/PRS.0000000000004228.
- Background: PubMed 39639229Zhu D, Lin YD, Yao YZ, Qi XJ, Qian K, Lin LZ. Negative association of C-reactive protein-albumin-lymphocyte index (CALLY index) with all-cause and cause-specific mortality in patients with cancer: results from NHANES 1999-2018. BMC Cancer. 2024 Dec 5;24(1):1499. doi: 10.1186/s12885-024-13261-y.
- Background: PubMed 34859834Tonga F, Bahadir S. The Factors Associated with Carpal Tunnel Syndrome Severity. Turk Neurosurg. 2022;32(3):392-397. doi: 10.5137/1019-5149.JTN.34519-21.2.
- Background: PubMed 38606315Zvonickova K, Rhee A, Sandy-Hindmarch O, Furniss D, Wiberg A, Schmid AB. Systemic low-grade C-reactive protein is associated with proximal symptom spread in carpal tunnel syndrome. Pain Rep. 2024 Apr 10;9(3):e1156. doi: 10.1097/PR9.0000000000001156. eCollection 2024 Jun.
- Background: PubMed 31875987Gunes M, Buyukgol H. Correlation of neutrophil/lymphocyte and platelet/lymphocyte ratios with the severity of idiopathic carpal tunnel syndrome. Muscle Nerve. 2020 Mar;61(3):369-374. doi: 10.1002/mus.26791. Epub 2020 Jan 9.
- Background: PubMed 36860868Wang RH, Wen WX, Jiang ZP, Du ZP, Ma ZH, Lu AL, Li HP, Yuan F, Wu SB, Guo JW, Cai YF, Huang Y, Wang LX, Lu HJ. The clinical value of neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), platelet-to-lymphocyte ratio (PLR) and systemic inflammation response index (SIRI) for predicting the occurrence and severity of pneumonia in patients with intracerebral hemorrhage. Front Immunol. 2023 Feb 13;14:1115031. doi: 10.3389/fimmu.2023.1115031. eCollection 2023.
- Background: PubMed 36217059Malakootian M, Soveizi M, Gholipour A, Oveisee M. Pathophysiology, Diagnosis, Treatment, and Genetics of Carpal Tunnel Syndrome: A Review. Cell Mol Neurobiol. 2023 Jul;43(5):1817-1831. doi: 10.1007/s10571-022-01297-2. Epub 2022 Oct 10.
- Background: PubMed 36525982Padua L, Cuccagna C, Giovannini S, Coraci D, Pelosi L, Loreti C, Bernabei R, Hobson-Webb LD. Carpal tunnel syndrome: updated evidence and new questions. Lancet Neurol. 2023 Mar;22(3):255-267. doi: 10.1016/S1474-4422(22)00432-X. Epub 2022 Dec 13.
- Background: PubMed 12169318Werner RA, Andary M. Carpal tunnel syndrome: pathophysiology and clinical neurophysiology. Clin Neurophysiol. 2002 Sep;113(9):1373-81. doi: 10.1016/s1388-2457(02)00169-4.
- Background: PubMed 35735622Otelea MR, Nartea R, Popescu FG, Covaleov A, Mitoiu BI, Nica AS. The Pathological Links between Adiposity and the Carpal Tunnel Syndrome. Curr Issues Mol Biol. 2022 Jun 8;44(6):2646-2663. doi: 10.3390/cimb44060181.
- Individual participant dataSharing planned: No. Individual participant data will not be shared due to institutional policies regarding patient privacy and data protection regulations
Related trials for Carpal Tunnel Syndrome (CTS)
Not yet recruitingObservational study
Postural Control and Balance Performance in Patients With Carpal Tunnel Syndrome
Carpal Tunnel Syndrome (CTS), Postural Assessment
Recruiting
Comparison of Wrist Splint Positions in Carpal Tunnel Syndrome
Carpal Tunnel Syndrome (CTS), Peripheral Neuropathies
Recruiting
Effects of Repetitive Peripheral Magnetic Stimulation(rPMS) on CTS(Carpal Tunnel Syndrome)
Carpal Tunnel Syndrome (CTS)
Recruiting
Hand Function Outcome After the Application of Transfer Energy Capacitive and Resistive on Post-burn Patients Presented With Carpal Tunnel Syndrome
Carpal Tunnel Syndrome (CTS) Post-burn
Not yet recruiting
Effect of Progressive Gamified Motor Rehabilitation After Carpal Tunnel Release
Carpal Tunnel Surgery
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Nadide Koca, M.D. principal investigator
University of Health Sciences, Ankara Training and Research Hospital, TURKEY
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Carpal Tunnel Syndrome (CTS) and Biomarkers / Blood, run by Ankara Training and Research Hospital at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evaluation of Systemic Inflammation Response Index (SIRI) as an Inflammatory Marker (time frame: up to 4 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06952647, which also lists 14 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Aug 2026.